退行性二尖瓣疾病微创手术安全性与成功的预测因素
该单中心研究纳入2002至2020年因二尖瓣脱垂接受微创手术的686例患者,评估围术期安全与手术成功的预测因素。结果显示,无三尖瓣病变需修复是安全的独立预测因素(HR 0.460),使用人工腱索是手术成功的独立预测因素(0.27)。后叶病变者无再手术生存率更高(log-rank P=0.002),病变位置而非修复方法是其独立预测因素(HR 1.455)。
要点
- 无三尖瓣病变需修复是围术期安全的独立预测因素(HR 0.460,P=0.033)。
- 使用人工腱索是手术成功的唯一独立预测因素(HR 0.27,P=0.022)。
- 后叶病变者无再手术生存率高于其他位置(log-rank P=0.002)。
核心结论
- 在退行性二尖瓣疾病的微创手术中,人工腱索置换比瓣叶切除获得更高的围术期成功率。
- 后叶病变是无再手术生存率的独立预测因素。
研究设计与样本
- 单中心研究,纳入2002至2020年因二尖瓣脱垂接受手术的686例患者(平均年龄60.5岁,标准差12.3岁,69.4%为男性)。
- 排除合并其他疾病、再次手术或非退行性二尖瓣病变的患者。
- 采用单变量和多变量分析识别围术期成功与安全的预测因素,并用Cox回归评估脱垂位置和修复技术对无再手术生存率的影响。
主要发现
- 二尖瓣修复率为94.6%,需同期三尖瓣修复者为16.5%。
- 围术期死亡5例(0.7%)。
- 围术期安全标准达标646/686例(94.2%),手术成功标准达标648/686例(94.5%)。
- 无三尖瓣病变需修复是安全的唯一独立预测因素(HR 0.460,95%CI 0.225-0.941,P=0.033)。
- 使用人工腱索是手术成功的唯一独立预测因素(HR 0.27,95%CI 0.09-0.83,P=0.022)。
关键数值与推荐
- 围术期安全定义为:无围术期死亡、心肌梗死、卒中、使用体外膜肺氧合或因出血再次手术。
- 手术成功定义为:初次二尖瓣修复成功,未转为置换或扩大胸廓切口,出院时无残余二尖瓣反流>轻度,且30天内无再手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to identify predictors of periprocedural success and safety in minimally invasive mitral valve surgery and to determine the impact of pathology localization and repair technique on reoperation-free survival. METHODS: We isolated 686 patients (mean age 60.5, standard deviation 12.3 years, 69.4% male) who underwent surgery for mitral valve prolapse between 2002 and 2020 in a single institution. Patients with concomitant disease, redo or mitral pathology other than degenerative mitral disease were excluded from the analysis. Periprocedural safety was defined as: freedom from perioperative death, myocardial infarction, stroke, use of extracorporeal membrane oxygenation or reoperation for bleeding. Operative success was defined as: successful primary mitral repair without conversion to replacement or to larger thoracic incisions, without residual mitral regurgitation > mild at discharge or reoperation within 30 days. Predictors for perioperative success and safety were identified using univariable and multivariable analyses. The impact of prolapse localization and repair technique on reoperation-free survival was assessed by Cox regression. RESULTS: The mitral repair rate and the need for concomitant tricuspid repair were 94.6% and 16.5%, respectively. Perioperative mortality occurred in 5 patients (0.7%). The criteria for perioperative safety and success were met in 646/686 (94.2%) and 648/686 (94.5%) patients, respectively. The absence of tricuspid disease requiring repair was the only independent predictor of safety in this cohort [hazard ratio (HR) 0.460 (0.225-0.941), P = 0.033]. The only independent predictor of operative success was the use of chordal replacement [0.27 (0.09-0.83), P = 0.022]. Reoperation-free survival was 98.5%, 94.5% and 86.9% at 1, 5 and 10 years, respectively. Posterior leaflet pathology demonstrated a higher reoperation-free survival as compared to other localizations (log-rank P = 0.002). The localization of leaflet pathology but not the repair method was an independent predictor for reoperation-free survival (HR 1.455, 95% confidence interval 1.098-1.930; P = 0.009). CONCLUSIONS: In minimally invasive mitral surgery for degenerative disease, chordal replacement yields higher rates of periprocedural success than leaflet resection. Posterior leaflet pathology is an independent predictor of reoperation-free survival.
引用
- Bonaros N, Hoefer D, Oezpeker C, et al. Predictors of safety and success in minimally invasive surgery for degenerative mitral disease. Eur J Cardiothorac Surg. 2022. PMID: 34738105. doi:10.1093/ejcts/ezab438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。